Advertisement

The first patient has been enrolled in a pilot study by Repligen Corp. for a compound that is intended to improve the detection of pancreatic cancer when using CT or MRI scans.

Ultimately, Waltham-based Repligen (Nasdaq: RGEN) will enroll up to 40 patients in the trial, all of whom have a known or suspected pancreatic mass, and the presence of a tumor will be confirmed by either surgery or biopsy. The pilot will be conducted at University Hospitals Case Medical Center in Cleveland, Ohio, which is affiliated with Case Western University.

SOURCE

Advertisement
Advertisement